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Aims To explore the influence of obesity on prognosis in high-risk patients with myocardial infarction (MI) or heart failure (HF).
Methods
and results
Individual data of 21 570 consecutively hospitalized patients from five Danish registries were pooled together. After a
follow-up of 10.4 years, all-cause mortality using multivariate model and adjusted hazard ratios (HR) with 95% con-
fidence intervals were calculated. Compared with normal weight [body mass index (BMI) 18.5–24.9 kg/m2], obesity
class II (BMI  35 kg/m2) was associated with increased risk of death in patients with MI but not HF [HR ¼ 1.23
(1.06–1.44), P ¼ 0.006 and HR ¼ 1.13 (0.95–1.36), P ¼ 0.95] (P-value for interaction ¼ 0.004). Obesity class I
(BMI 30–34.9 kg/m2) was not associated with increased risk of death in MI or HF [HR ¼ 0.99 (0.92–1.08) and
1.00 (0.90–1.11), P . 0.1]. Pre-obesity (BMI 25–29.9 kg/m2) was associated with decreased death risk in MI but
not HF [HR ¼ 0.91 (0.87–0.96), P ¼ 0.0006 and 1.04 (0.97–1.12), P ¼ 0.34] (P-value for interaction ¼ 0.007).
Underweight (BMI, 18.5 kg/m2) patients were in increased death risk regardless of MI or HF [HR ¼ 1.54 (1.35–
1.75) and 1.37 (1.18–1.59), P, 0.001].
Conclusion In patients with MI but not HF, the relationship between BMI and mortality is U-shaped with highest mortality in
underweight and obese class II, but lowest in the other BMI classes.
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Introduction
Obesity is associated with an increased risk of mortality and
myocardial infarction (MI) in the general population,1,2 but appar-
ently not in high-risk patients with MI or chronic heart failure
(HF), where obesity in several studies appears even to be associ-
ated with a favourable prognosis.3–9 The current recommendation
for overweight patients with MI or HF is to lose weight despite the
observational studies10,11 and is based provisionally on the logical
implications of improved risk factors with weight loss. Most of
the cited studies are based on selected populations participating
in randomized controlled trials of patients with MI or HF. The
studies’ sizes limit their statistical power and most have included
only a minority of patients who were severely obese. Recently, a
meta-analysis based on summary data of several cohort studies
including patients with MI showed an increased risk of cardiovascu-
lar, but not of total mortality in severely obese patients.12 So, the
prognosis of high-risk obese and pre-obese patients with MI or HF
needs to be further clarified. We therefore pooled a series of
registries that specifically included consecutively hospitalized
patients with either MI or HF, and who were investigated and
analysed in a single core laboratory. This enabled us to study a
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large sample of unselected patients with a high risk of death and
with sufficient power to study all weight classes. We aimed to
examine whether the results were consistent with the previous
studies or not and to explore the outcome in a large-scale study
with patients characterized by high long-term mortality rates and
distinguish between those with MI and HF.
Methods
We combined five registries where patients were included consecu-
tively after an MI or after admission with HF in the same country,
and where all participating centres have complete regional coverage
for these patients. Each register was formed during screening for a
clinical trial, and with a dedicated staff responsible for consecutive
screening. These registries were: the Trandolapril in Cardiac Evaluation
(TRACE) study, the Danish Investigations of Arrhythmia and Mortality
HF (DIAMOND-HF) study, the DIAMOND-Acute Myocardial Infarc-
tion (DIAMOND-MI) study, the Bucindolol Evaluation in Acute Myo-
cardial Infarction Trial (BEAT), and finally the Echo Cardiography
and Heart Outcome Study (ECHOS). The designs of these studies
have been published previously.13–16 BMI data on TRACE and
DIAMOND-HF studies have been published before.7,17 The TRACE
(n ¼ 6676), BEAT (n ¼ 2978), and DIAMOND-MI (n ¼ 7974) regis-
tries included patients after MI, while DIAMOND-HF (n ¼ 5177) and
ECHOS (n ¼ 2904) registries included patients with HF. Overall,
these registries constituted 26 578 patients. After data combination,
the total population of these five registries constituted 25 709 patients.
The reason for the fall in the number was due to exclusion of duplicate
patients who had participated in one and later in another study. BMI
was not available in 4139 patients, i.e. 16% of the total population.
The main reason for missing BMI data was the inappropriate recording
by the investigators. Finally, a total of 21 570 patients characterized by
MI and/or HF with available BMI were left for analyses (Table 1).
In these registries, the baseline demographic values, weight and
height of all patients were recorded to calculate BMI. Left ventricular
systolic function was evaluated centrally from echocardiograms for
all patients. Echocardiograms were recorded on videotape and wall
motion index (WMI) was calculated in the same core laboratory by
experienced investigators.18 We used a reverse scoring system for
WMI, where WMI multiplied by 30 corresponded roughly to ejection
fraction.19 Creatinine clearance was calculated from serum creatinine
values using the Cockroft and Gault method.20 Information on hyper-
tension, previous ischaemic heart disease (IHD), diabetes, and previous
MI was based on patient interview and chart review. The presence or
absence of chronic obstructive pulmonary disease (COPD) was
decided and reported by the investigator based on patient history
and hospital records.
The primary endpoint was death from all causes and was reported
by the Danish Central Personal Registry, where all deaths in Denmark
were registered within 2 weeks. In May 2006, an interrogation of this
register provided a mean follow-up of 10.4 years (range 2.9–16.4) for
all surviving patients included in the current study. Of the total of
21 570 registered patients, survival data were unavailable for 51
patients who had emigrated and 20 who had disappeared.
Statistics
The individual patient data reported in the five registries were com-
bined and analysed using the SAS (SAS Institute, Cary, NC, USA)
version 9.1. Patients were divided into five pre-specified BMI groups
using the World Health Organization (WHO) classification: BMI,
18.5 kg/m2 denotes underweight, 18.5–24.9 kg/m2 denotes normal
weight, 25–29.9 kg/m2 denotes pre-obese, 30–34.9 kg/m2 denotes
obese class I, and 35 kg/m2 denotes obese class II.21 Continuous base-
line variables in different BMI groupswere presented as medians with 5%
and 95% percentiles and were analysed using Kruskal–Wallis test, while
the discrete variables were analysed by chi-squared test.
Univariable Cox analyses were performed to identify survival pre-
dictors. Multivariable model was constructed to assess all available
covariates: age, gender, BMI, WMI, creatinine clearance, diabetes,
history of hypertension, previous MI, history of IHD, HF, smoking,
and COPD (Table 2), but use of medical treatment was not included
in the model because of the potential risk of selection bias as patients
were not randomized to their treatment regime. Each BMI group was
entered as an independent variable using normal weight as reference.
Relative risks with 95% confidence intervals were calculated as hazard
ratios obtained from the Cox proportional hazard models. Thus,
adjusted hazard ratios with 95% CI for all baseline variables except
for use of medical treatment were generated from this model. The
final model was checked for assumptions. The proportional hazard
assumption was checked graphically [log survival vs. log(2log survival
distribution function)] as well as studying a time dependent variable
(lifetime  variable). No significant deviations from the proportional
hazard assumption were identified. Linearity was studied by adding,
to the model, quintiles of a variable along with the continuous variable.
If the set of quintiles were without importance, linearity was accepted.
Statistical significant deviations were found for creatinine clearance, but
the importance of BMI in subgroups of creatinine clearance was nearly
identical and creatinine clearance was therefore used as a continuous
variable. Linearity of BMI was studied similarly using the predefined
groups. The deviation from linearity was significant with P, 0.0001.
Finally, interaction was tested with a likelihood ratio test in the final
multivariable model using a P-value of 0.01 as significant. There was sig-
nificant interaction with WMI driven by the important difference
between WMI in patients with and without underweight.
The survival plots for the five BMI groups were constructed by the
Kaplan–Meier method.
Since the BEAT registry provided creatinine clearance only in a min-
ority of patients, the multivariable analyses were performed both with
and without the inclusion of this registry. The five registries separately
and the three MI registries (TRACE, DIAMOND-MI, and BEAT) vs. the
two HF registries (DIAMOND-HF and ECHOS) were entered in the
model as class variables. Interaction analyses were performed to
explore heterogeneity. Furthermore, the groups of MI and HF regis-
tries were entered in the multivariable model also as 0-1 variables
to test any change in the outcomes compared with the original
model. All P-values are two-tailed and values below 0.05 were con-
sidered statistically significant.
Results
Baseline demography and characteristics of the five registries and
that of the analysed 21 570 patients’ individual data with available
BMI groups are presented in Tables 1 and 2, respectively. Of the
total population, 15 091 patients had MI and 6479 had HF. There
were significant differences between the five BMI groups. Com-
pared with the normal BMI group, the underweight BMI group
included a significantly higher number of older patients, females,
and smokers. These patients were generally characterized by
lower WMI and lower creatinine clearance, and had more often
HF, IHD, and COPD. Conversely, obese class I and II included sig-
nificantly higher numbers of younger patients, who were more
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Table 1 Baseline demography and characteristics of the included five registries
Characteristic TRACE DIAMOND-HF DIAMOND-MI BEAT ECHOS
Total number 6676 5177 7974 2978 2904
Patients with available BMI 6169 4412 6936 1986 2067
Register period (year) 1990–1992 1993–1996 1993–1996 1998–1999 2001–2003
Follow-up period (year) median (range) 14.8 (13.9–16.4) 11.3 (10.4–12.5) 10.9 (9.9–12.5) 7.2 (6.4–8.3) 4.5 (2.9–5.5)
All-cause mortality (%) 4945 (74) 4349 (84) 4433 (56) 1267 (43) 1538 (53)
Age (year) median (range) 68.5 (47–84) 73.0 (53–86) 68.0 (46–83) 68.7 (46–86) 75.0 (53–89)
Gender (male) % 67.5 59.9 69.8 67.3 60.2
Body mass index (kg/m2) 25.4 (20–33) 25.4 (19–35) 25.8 (20–33) 25.9 (20–34) 25.8 (19–36)
Wall motion index (median) 1.4 (0.7–2.0) 1.4 (0.6–2.0) 1.6 (0.9–2.0) 1.6 (0.8–2.0) 1.4 (0.5–2.0)
Creatinine clearance (mL/min) 66.2 (30–118) 52.4 (23–106) 66.5 (29–123) NA 57.6 (24–126)
History of diabetes (%) 10.8 16.2 10.3 13.2 15.2
History of hypertension (%) 22.6 24.4 23.9 24.1 26.9
History of IHD (%) 43.7 54.3 40.6 34.6 40.8
History of COPD (%) 11.5 22.5 9.5 9.6 24.0
Previous MI (%) 23.4 33.3 20.4 22.3 26.8
HF (%) 53.6 100 40.9 44.5 100
Smokers (%) 51.5 34.0 49.7 45.2 29.1
TRACE, Trandolapril in Cardiac Evaluation study; DIAMOND-HF, the Danish Investigations of Arrhythmia and Mortality HF study; DIAMOND-MI, the DIAMOND-Acute Myocardial Infarction study; BEAT, the Bucindolol Evaluation in
Acute Myocardial Infarction Trial; ECHOS, Echo Cardiography and Heart Outcome Study; BMI, body mass index; COPD, chronic obstructive pulmonary disease; IHD, ischaemic heart disease; HF, heart failure; MI, myocardial infarction; NA,






 by guest on January 14, 2017 http://eurheartj.oxfordjournals.org/ Downloaded from 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Baseline characteristics of all patients in the five registries according to weight classes
Variable Under weight (n 5 638) Normal weight (n5 8600) Pre-obese (n 5 8854) Obese class I (n 5 2714) Obese class II (n5 764) P-value
Age (year) 75.5 (54–89) 71.4 (48–86) 68.3 (47–84) 66.6 (46–82) 63.4 (45–80) ,0.001
Gender (male) 175 (27.5) 5254 (61.1) 6665 (75.3) 1923 (70.9) 447 (58.6) ,0.001
Body mass index (kg/m2) 17.4 (14.5–18.4) 22.9 (19.5–24.7) 27.0 (25.1–29.4) 31.5 ( 30.1–34.4) 37.2 (35.1–46.6) ,0.001
Wall motion index 1.3 (0.5–2.0) 1.4 (0.6–2.0) 1.5 (0.7–2.0) 1.6 (0.7–2.0) 1.6 (0.7–2.0) ,0.001
Creatinine clearance (mL/min) 36.4 (17.1–71.5) 53.2 (24.7–96.6) 68.1 (32.2–117.0) 80.6 (38.1–137.9) 98.1 (45.7–178.6) ,0.001
Diabetes 43 (6.8) 883 (10.3) 1041 (11.8) 502 (18.5) 184 (24.0) ,0.001
History of hypertension 117 (18.4) 1726 (20.1) 2185 (24.7) 835 (30.8) 295 (38.5) ,0.001
Previous MI 182 (28.5) 2148 (25.0) 2339 (26.4) 634 (23.4) 166 (21.7) ,0.001
HF 483 (75.9) 5426 (63.1) 5181 (58.5) 1751 (64.6) 543 (70.9) ,0.001
Smokers 332 (52.6) 4060 (47.8) 3836 (43.9) 1083 (40.2) 292 (38.6) ,0.001
COPD 174 (27.3) 1303 (15.2) 1076 (12.2) 404 (14.9) 143 (18.7) ,0.001
IHD 291 (45.7) 3762 (43.8) 4035 (45.6) 1152 (42.4) 312 (40.7) 0.004
ACE-I at dischargea 209 (44.1) 2481 (41.4) 2480 (39.7) 889 (43.3) 296 (47.4) ,0.001
Beta-blocker at dischargea 65 (28.6) 1042 (40.4) 1281 (50.1) 407 (47.1) 132 (44.6) ,0.001
Age, body mass index, wall motion index and creatinine clearance are presented as medians with 5% and 95% percentiles. The other variables are presented as numbers with percentages. ACE-I, angiotensin-converting enzyme-inhibitor;
COPD, chronic obstructive pulmonary disease; CI, confidence interval; HF, heart failure; IHD, ischaemic heart disease; MI, myocardial infarction; N, number.
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often male, with higher prevalence of diabetes and hypertension
and a significant number of them used life-prolonging agents
like angiotensin-converting enzyme-inhibitors (ACE-I) and beta-
blockers.
Analysis of mortality
In the univariable model, only the underweight class was associated
with a clearly increased death risk [HR ¼ 1.74 (1.57–1.92), P,
0.0001], whereas other BMI groups appeared similar. In the multi-
variable model (Table 3), underweight class was again associated
with increased mortality risk [HR ¼ 1.46 (1.32–1.60), P, 0.001],
but now the obese class II was also associated with an independent
increased mortality risk [HR ¼ 1.15 (1.03–1.30), P ¼ 0.013]
(Figure 1). The relationship between BMI and mortality risk fol-
lowed a U-shaped curve with the lowest mortality in normal
weight, pre-obese, and obese class I patients and with the risk of
death highest in the underweight and obese class II. The analysis
of the subgroup of patients with MI showed a similar pattern
(Table 3) and followed a U-shaped curve (Figure 2A) with a
decreased death risk in pre-obese class [HR ¼ 0.91 (0.87–0.96)]
and increased death risk for underweight [HR ¼ 1.54 (1.35–
1.75), P, 0.001] and for obese class II [HR ¼ 1.23 (1.06–1.44),
P ¼ 0.0065] (Table 3). In contrast to MI, the analysis on HF patients
showed an increased death risk only in underweight class [1.37
(1.18–1.59), P, 0.001] without any increased death risk in
obese class I [HR ¼ 1.00 (0.90–1.11), P ¼ 0.96] or obese class II
[HR ¼ 1.13 (0.95–1.36), P ¼ 0.14] (Table 3 and Figure 2B). Age,
male gender, WMI, creatinine clearance, presence of diabetes,
history of hypertension, IHD, previous MI, smoking, and COPD
were all independent mortality predictors (Table 3).
Interaction analyses
In the multivariable model, the interaction analyses were insignifi-
cant between BMI groups and all included covariates except for
WMI. Importantly, the interactions were not significant for age,
gender, and admission year in any of the BMI groups. There was
a significant interaction between underweight and WMI (P,
0.001) indicating that with increasing WMI, the HR increased
from 1.15 (0.92–1.44) in patients with WMI, 0.8 to 1.87
(1.60–2.20) in patients with WMI. 1.6.
There was a significant interaction between BMI groups and MI/
HF registries as demonstrated in Figure 2A and B. The interactions
were significant for pre-obese (P ¼ 0.007) and obese class II
patients (P ¼ 0.004).
There was insignificant interaction between MI and HF registries
(P ¼ 0.207) and also between the five registries separately
(P ¼ 0.057).
Other analyses
Subgroup analysis in patients with normal creatinine clearance
showed that underweight was associated with an HR of 1.79
(1.31–2.44), P, 0.001 when compared with normal weight
patients. The interaction between BMI and WMI only in the sub-
group of HF patients showed that WMI. 1.2 (non-systolic left
ventricle dysfunction) was associated with a significant increased
mortality risk in underweight patients [HR ¼ 1.85 (1.48–2.31),
P, 0.001], while WMI  1.2 (systolic left ventricle dysfunction)
was associated with increased mortality risk in obese class II
patients [HR ¼ 1.45(1.11–1.90), P ¼ 0.0057]. Thus, the relation-
ship between BMI and WMI in HF patients with WMI  1.2 was
U-shaped as in the MI patients.
Because the BEAT registry did not provide serum creatinine
levels in all patients, the results were repeated with and without
inclusion of the BEAT registry. The results for BMI groups were
unchanged. The results were also unchanged after inclusion of
groups of MI or HF registries as 0–1 variables in the multivariable
model.
Analyses for BMI linearity in the whole population showed a sig-
nificant deviation with a chi-square value of 52 and P, 0.001. The
MI population showed a clear deviation from linearity with a
chi-square value of 56 and P, 0.001, which was in concordance
with a U shape in the multivariable model results. The deviation
from linearity was less clear in HF population with a chi-square
value of 12 and P ¼ 0.016.
Discussion
The important finding of this pooled analysis of unselected con-
secutive hospitalized patients is that both underweight and obese
class II patients with MI do have increased death risk. This
finding is consistent with some previous studies that have shown
an increased risk of total mortality associated with high BMI,22,23
but simultaneously inconsistent with other studies which have
shown an inverse correlation.7,24–26 This finding is also in disagree-
ment with the result of the meta-analysis by Romero-Corral,12
who found a decreased total mortality risk in mild and severe
obese patients. However, Romero-Corral demonstrated that
severe obese MI patients, but not mild obese or overweight
ones, had still an increased cardiovascular mortality. The authors
attributed their finding to a possible lack of the discriminatory
power of BMI measurements to differentiate between body fat
and lean mass. The different finding in our study may reflect the
adequate statistical power provided by the systematic inclusion
of unselected consecutive populations with a detailed record of
risk factors and a long period of follow-up.
Recently, it has also been suggested that waist or waist-to-hip
ratio (WHR) are stronger predictors of adverse cardiovascular
events than BMI.2 In our study, BMI and not WHRs were available
in the majority of patients, but BMI was able to discriminate the
impact of severe levels of obesity. It is, however, likely that the
BMI value in the overweight or obese class I group in particular
includes a wide range of patients with different proportions of
body fat for their BMI and with very different degrees of abdominal
obesity. The current results cannot therefore be used to reassure
the moderately overweight about their risk, which seems more
responsive to increases in body fat and its abdominal distribution.
The other finding of the current study was that obesity in HF in
the same cohort was not associated with increased death risk,
which was consistent with some previous studies.3,4,8 Importantly,
the previously described paradox that obese patients with HF have
a lower mortality is not substantiated by our data. There was a
strong tendency towards a U-shaped relation between BMI
groups and hazard of death (Figure 2B). Secondly, we have in
previously published data on the DIAMOND-HF study by
J. Abdulla et al598






Gustafsson17 highlighted the importance of the interaction
between obesity and systolic dysfunction that may increase death
risk. This finding was reaffirmed in the current study even after
combining the ECHOS study with the DIAMOND-HF study. The
increased mortality risk in underweight HF patients with WMI.
1.2, as well as in obese class II with WMI, 1.2 is important. As
HF, in contrast to MI, is a complex syndrome encompassing
patients with both systolic and non-systolic dysfunction, it may
be important to differentiate these categories concerning risk
factors, though the prognosis is generally poor. Patients with HF
and systolic dysfunction (WMI  1.2) overlap many characteristics
with those having MI and systolic dysfunction and the management
of both is similar. Interestingly, the hazard of death for HF patients
with systolic dysfunction followed a U-shaped curve, which was
similar to that one for MI patients in this study. This may indicate
a possible common mechanism behind the increased death risk for
both categories. Our finding is in contrast to that described by
authors of the Candesartan in Heart Failure: Assessment of
Reduction in Mortality and morbidity (CHARM) study.27
In the current study, obese patients were more often younger
males, had better left systolic ventricular function, better renal
function, and had fewer episodes of previous MI, HF, and IHD.
The obese patients did have more cases of diabetes and hyperten-
sion, but it is likely that these risks were ameliorated by the coex-
isting use of the well-documented medications including ACE-I and
beta-blockers that improve survival. The adjusted multivariable
models highlight the importance of other risk factors in determin-
ing mortality. This was re-emphasized by our reaffirmation, from
this large data set, of the importance of age as a strong predictor
of mortality as in both the general population and in those with MI
or HF. Furthermore, a history of hypertension, diabetes, left ventri-
cular dysfunction, COPD, smoking, previous MI, and low creatinine
clearance were all predictors of mortality.
These analyses imply that obesity needs to be considered an
important risk factor in patients with MI or HF with systolic dys-
function, and we find no evidence of any protective effect of
obesity. This analysis may also emphasize the importance of study-
ing a large, high-risk population over a prolonged period of time
(10.4 years) and having well-documented left ventricular systolic
function by analysing all the data in a single core laboratory. The
current study was also statistically powerful, given a mortality
rate of more than 50%. Nevertheless, prospective interventional
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Table 3 Results of the multivariable analyses for the whole population and subgroups with myocardial infarction and
heart failure according to weight classes and other predictors
Variable Hazard ratio (95% CI) Parameter estimate Standard error of estimate P-value
Body mass index groups compared with normal weight
Underweight—all 1.46 (1.32–1.60) 0.379 0.049 ,0.001
Underweight—MI 1.54 (1.35–1.75) 0.434 0.065 ,0.001
Underweight—HF 1.37 (1.18–1.59) 0.318 0.074 ,0.001
Normal weight (all, MI, HF) 1.00 – – –
Pre-obese—all 0.95 (0.91–0.99) 20.047 0.021 0.024
Pre-obese—MI 0.91 (0.87–0.96) 20.088 0.025 0.0006
Pre-obese—HF 1.04 (0.97–1.12) 0.042 0.037 0.34
Obese class I—all 0.99 (0.93–1.06) 20.006 0.033 0.84
Obese class I—MI 0.99 (0.92–1.08) 0.115 0.041 0.94
Obese class I—HF 1.00 (0.90–1.11) 0.002 0.054 0.96
Obese class II—all 1.15 (1.03–1.30) 0.147 0.059 0.013
Obese class II—MI 1.23 (1.06–1.44) 0.213 0.078 0.0065
Obese class II—HF 1.13 (0.95–1.36) 0.128 0.092 0.14
Other important predictors of mortality in the whole population
Age 1.04 (1.04–1.05) 0.046 0.001 ,0.001
Gender (male) 1.19 (1.15–1.24) 0.176 0.020 ,0.001
Wall motion index 0.57 (0.55–0.60) 20.558 0.021 ,0.001
Creatinine clearance 0.99 (0.99–0.99) 20.009 0.001 ,0.001
Heart failure 1.73 (1.65–1.81) 0.547 0.023 ,0.001
Diabetes mellitus 1.51 (1.43–1.59) 0.409 0.026 ,0.001
History of hypertension 1.12 (1.08–1.17) 0.117 0.021 ,0.001
Previous MI 1.14 (1.08–1.20) 0.132 0.025 ,0.001
Smoking 1.148 (1.10–1.19) 0.138 0.019 ,0.001
History of IHD 1.13 (1.08–1.19) 0.129 0.023 ,0.001
History of chronic obstructive pulmonary disease 1.43 (1.36–1.49) 0.354 0.024 ,0.001
CI, confidence interval; IHD, ischaemic heart disease; MI, myocardial infarction; HF, heart failure.
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trials are necessary to investigate whether weight reduction in
high-risk obese patients does indeed reduce the risk of death.
Limitations of the study
Despite the pooling of five registries’ data, this analysis was not a
systematic review of all available studies in the literature. We
also recognized the possibility of heterogeneity but the multi-
variate analyses showed no statistically significant heterogeneity
either between the five studies individually or between the MI
and HF populations. By including patients without discounting
the first few years of observation, we may also have confounded
the analyses of all-cause mortality particularly in underweight and
some normal weight patients who might have had conditions
such as cancer which could have both induced significantly
recent falls in BMI and amplified the observed mortality rate of
the groups. This is likely to be more important than BMI changes
during the follow-up period, which in practice are most likely
then to induce an underestimation of the prognostic importance
of BMI. The exclusion of a significant number of patients (16% of
the total) with unavailable BMI from the analyses has probably
caused some selection bias. The five registries had also different
inclusion periods ranging from 1990 to 2001, which may with
respect to the changes in the demography and treatment strategies
by time have confounded the results. Finally, fasting lipids was not
included as a variable in the study.
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